Lyell Immunopharma
LYEL
127 hedge funds and large institutions have $297M invested in Lyell Immunopharma in 2024 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 36 increasing their positions, 44 reducing their positions, and 13 closing their positions.
77% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 13
16% more capital invested
Capital invested by funds: $256M → $297M (+$40.5M)
8% more funds holding
Funds holding: 118 → 127 (+9)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0% less ownership
Funds ownership: 2.62% → 2.61% (-0%)
7% less call options, than puts
Call options by funds: $14K | Put options by funds: $15K
18% less repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 44
Top Buyers
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$7.18M |
| 2 |
Millennium Management
New York
|
+$2.44M |
| 3 |
JP Morgan Chase
New York
|
+$1.05M |
| 4 |
D.E. Shaw & Co
New York
|
+$800K |
| 5 |
Renaissance Technologies
New York
|
+$751K |
Top Sellers
| 1 |
Citadel Advisors
Miami,
Florida
|
-$5.76M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$3.09M |
| 3 |
Morgan Stanley
New York
|
-$1.18M |
| 4 |
HF
HRT Financial
New York
|
-$963K |
| 5 |
BlackRock
New York
|
-$877K |
LYEL Hedge Fund Activity: Q1 2024 in Review
127 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Lyell Immunopharma (LYEL) for Q1 2024, worth a combined $297M — up 16% from $256M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new LYEL positions and 13 closed out — a net gain of 10 holders — while 36 added to existing stakes and 44 trimmed.
The largest buyer was Opaleye Management, opening a new position worth an estimated $7.18M. The largest seller was Citadel Advisors, cutting an estimated $5.76M.
- 127 institutional investors held Lyell Immunopharma (LYEL) as of Q1 2024, up from 118 in Q4 2023.
- Funds reported $297M of Lyell Immunopharma stock for Q1 2024, up 16% quarter-over-quarter.
- 23 funds opened new Lyell Immunopharma positions in Q1 2024 and 13 closed out, a net change of +10 holders.
- The largest Lyell Immunopharma buyer in Q1 2024 was Opaleye Management, an estimated $7.18M added.
- The largest Lyell Immunopharma seller in Q1 2024 was Citadel Advisors, an estimated $5.76M sold.
Based on aggregated 13F filings for Q1 2024.